- Home
- PBT vs MLYS Comparison
PBT vs MLYS Comparison
Compare PBT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- MLYS
- Stock Information
- Founded
- PBT 1980
- MLYS 2019
- Country
- PBT United States
- MLYS United States
- Employees
- PBT N/A
- MLYS N/A
- Industry
- PBT Oil & Gas Production
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- MLYS Health Care
- Exchange
- PBT Nasdaq
- MLYS Nasdaq
- Market Cap
- PBT 562.6M
- MLYS 1.0B
- IPO Year
- PBT N/A
- MLYS 2023
- Fundamental
- Price
- PBT $12.91
- MLYS $14.54
- Analyst Decision
- PBT
- MLYS Strong Buy
- Analyst Count
- PBT 0
- MLYS 4
- Target Price
- PBT N/A
- MLYS $27.00
- AVG Volume (30 Days)
- PBT 131.4K
- MLYS 862.9K
- Earning Date
- PBT 01-01-0001
- MLYS 08-12-2025
- Dividend Yield
- PBT 4.22%
- MLYS N/A
- EPS Growth
- PBT N/A
- MLYS N/A
- EPS
- PBT 0.48
- MLYS N/A
- Revenue
- PBT $24,140,674.00
- MLYS N/A
- Revenue This Year
- PBT N/A
- MLYS N/A
- Revenue Next Year
- PBT N/A
- MLYS N/A
- P/E Ratio
- PBT $26.72
- MLYS N/A
- Revenue Growth
- PBT N/A
- MLYS N/A
- 52 Week Low
- PBT $8.01
- MLYS $8.24
- 52 Week High
- PBT $14.26
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- PBT 81.63
- MLYS 47.97
- Support Level
- PBT $12.32
- MLYS $13.22
- Resistance Level
- PBT $13.01
- MLYS $14.54
- Average True Range (ATR)
- PBT 0.31
- MLYS 0.71
- MACD
- PBT 0.05
- MLYS 0.00
- Stochastic Oscillator
- PBT 93.01
- MLYS 68.37
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.